Uliledlimab

Phase 3Monoclonal antibody

TTJ Biopharma Co., Ltd.

Uliledlimab is one of 38 small molecule programs targeting Non-Small Cell Lung Cancer. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Non-Small Cell Lung CancerActive, not recruiting

Non-Small Cell Lung CancerPhase 3

Active, not recruiting

Competition

Competitive Landscape

414 competitors in Non-Small Cell Lung Cancer

#DrugCompanyPhaseTrials

Taxol

Trodelvy

10 3

Navelbine

PPierre Fabre Medicament

Phase 3

24 4

Uliledlimab

TTJ Biopharma Co., Ltd.

Phase 3

2 5

Remeron

OOrganon and Co

Preclinical

1 6

Aqupla

Jiangsu Simcere Pharmaceutical Co., Ltd.

Preclinical

—7

Ftorafur

TThe First Affiliated Hospital with Nanjing Medical University

Preclinical

—8

Vibramycin

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Treatment

1 10

PD-1 Inhibitors

BBioNTech US Inc.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2028

Phase 2/3Active, not recruiting

Non-Small Cell Lung Cancer

NCT06984588

Q1 2029

Phase 2Active, not recruiting

Non-Small Cell Lung Cancer

NCT07005336

Clinical

Trials by Indication[1]

Non-Small Cell Lung Cancer2 trials

A Study to Compare Uliledlimab Combined With Toripalimab, Toripalimab Monotherapy, and Pembrolizumab Monotherapy in Patients With Previously Untreated Locally Advanced Unresectable or Metastatic PD-L1- and CD73- Selected Non-Small Cell Lung Cancer

Active, not recruiting·TTJ Biopharma Co., Ltd.·Phase 2/3·NCT06984588·450 enrolled

A Study to Compare Uliledlimab Combined With Sintilimab and Chemotherapy Versus Sintilimab Combined With Chemotherapy in Patients With Previously Untreated Locally Advanced Unresectable or Metastatic Non-small Cell Lung Cancer

Active, not recruiting·TTJ Biopharma Co., Ltd.·Phase 2·NCT07005336·150 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Uliledlimab. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Uliledlimab compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Uliledlimab. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — TJ Biopharma Co., Ltd. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Monoclonal antibody[2]
Highest Phase: Phase 3[1]
Company: TTJ Biopharma Co., Ltd.

Uliledlimab

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2028

Q1 2029

Trials by Indication[1]

Non-Small Cell Lung Cancer2 trials

References

Drug Info

Quick Facts

Related News